← Browse by Condition
Medical Condition
intrahepatic cholangiocarcinoma
Total Trials
6
Recruiting Now
6
Trial Phases
Phase 2, EARLY_Phase 1
NCT06728410 Phase 2
Recruiting
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Enrollment
38 pts
Location
United States
Sponsor
Mehmet Akce
NCT06313203 Phase 2
Recruiting
HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)
Enrollment
39 pts
Location
Norway
Sponsor
Oslo University Hospital
NCT06505486
Recruiting
GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC
Enrollment
21 pts
Location
China
Sponsor
Sun Yat-Sen Memorial Hospital ...
NCT05422690 Phase 2
Recruiting
The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer
Enrollment
16 pts
Location
United States
Sponsor
Inova Health Care Services
NCT05223816 Phase 2
Recruiting
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Enrollment
97 pts
Location
United States
Sponsor
Virogin Biotech Canada Ltd
NCT06583993 EARLY_Phase 1
Recruiting
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Advanced ICC Patients
Enrollment
9 pts
Location
China
Sponsor
Shanghai Changzheng Hospital